Matthew Baker Email

CEO . Neophore

Current Roles

Employees:
20
Revenue:
$3.1M
About
NeoPhore is creating novel small molecule immuno-oncology therapeutics. NeoPhore's drugs target genetic mechanisms that both clinical and lab validation studies suggest will promote neoantigen creation and diversity across numerous cancers. Alone or in combination with other cancer immunotherapies, drugs that spark cancer neoantigen creation are designed to stimulate the immune system and improve outcomes for patients who fail to benefit from the current generation of cancer immunity therapeutics.
Neophore Address
1 Ashley Road
Cambridge, null
Neophore Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.